Compound News and Research

RSS

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

In response to a European Commission consultation on the EU Clinical Trials Directive, ECCO - the European CanCer Organisation - has supported proposals by its member organisations for adapting the Directive's requirements to reflect practical necessities in cancer research and treatment.

29 Jan 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

FDA cautions drug makers about potential abuse

The Los Angeles Times reports that the Food and Drug Administration "this week released a draft of voluntary guidelines to assist drug makers in figuring out which compounds should be placed under the Controlled Substances Act. The law regulates the handling, record-keeping and dispensing of drugs deemed to be dangerous or addictive if misused -- in some cases imposing criminal penalties for misuse.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Blocking CRF may prevent excessive alcohol consumption

A team of scientists from The Scripps Research Institute has found that a specific stress hormone, the corticotropin-releasing factor (CRF), is key to the development and maintenance of alcohol dependence in animal models.

28 Jan 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

New scientific data reveals wood pallets present dangerous risks to our foods and medicines

Coming on the heels of the sweeping Tylenol recall, new scientific data from independent tests reveal more about the hidden dangers of wood pallets and the threat they pose to the foods we eat and the medications we rely on every day.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Restrictions should be placed on the use of Ginkgo biloba (G. biloba) - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes.

28 Jan 2010

MedCI forms new strategic alliance with Genta

MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated to secure licensing partners for Genta’s small molecule oncology compound, tesetaxel.

28 Jan 2010

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced the execution of an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI) to commence studies utilizing ImmuneRegen's Homspera.

28 Jan 2010

Epidemiological study shows Parkinson's disease is more common among whites and Hispanics

The largest epidemiological study of Parkinson's disease in the United States has found that the disease is more common in the Midwest and the Northeast and is twice as likely to strike whites and Hispanics as blacks and Asians.

28 Jan 2010

EU Clinical Trials Directive: ECCO supports proposals by its member organisations

27 Jan 2010

Proteomics study reveals protein suppression makes cancers more susceptible to chemotherapy

Taxanes, a group of cancer drugs that includes paclitaxel (Taxol-) and docetaxel (Taxotere-), have become front-line therapy for a variety of metastatic cancers. But as with many chemotherapy agents, resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers.

27 Jan 2010

Compound News and Research

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

FDA cautions drug makers about potential abuse

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Celgene reports total revenue of $758M for fourth-quarter of 2009

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Blocking CRF may prevent excessive alcohol consumption

Pfizer's new pipeline shows growth and diversity in research and development

New scientific data reveals wood pallets present dangerous risks to our foods and medicines

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

MedCI forms new strategic alliance with Genta

NIH to perform exploratory studies on ImmuneRegen BioSciences' Homspera

Epidemiological study shows Parkinson's disease is more common among whites and Hispanics

EU Clinical Trials Directive: ECCO supports proposals by its member organisations

Proteomics study reveals protein suppression makes cancers more susceptible to chemotherapy

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News